Hochul's budget threatens cancer care access for medicaid recipients
Albany – A legislative gambit within Governor Kathy Hochul’s proposed budget could significantly restrict access to biomarker testing for Medicaid recipients in New York, reversing a 2023 expansion hailed as a watershed moment in cancer care. Advocates warn the move, couched as a measure to ensure “patient safety,” could disproportionately impact vulnerable populations already facing systemic barriers to quality healthcare.
The shifting landscape of biomarker testing
Just three years ago, New York state took a significant stride forward when Governor Hochul signed legislation mandating insurance coverage, including Medicaid, for biomarker testing. This technology allows physicians to identify measurable indicators of disease and treatment response, tailoring therapies with unprecedented precision. But the current budget proposal introduces a new layer of scrutiny: a requirement for Medicaid enrollees to meet “medical necessity criteria” for coverage—a standard critics say is vague and potentially onerous.
The briefing book accompanying the budget states that all biomarker precision tests covered by Medicaid must now meet these criteria, effectively subjecting patients to additional hurdles. A spokesperson for the governor insists this isn't a rollback, framing it as a refinement to “further ensure patient safety in accordance with evidence-based and peer-reviewed guidelines.” However, the language has ignited fierce opposition from cancer survivors and advocacy groups.
Lexy Mealing, a breast cancer survivor who benefited directly from biomarker testing, shared her story outside the governor’s Manhattan office. “It was life-shattering,” she recalled of her diagnosis five years ago. She credits biomarker testing with guiding her physicians toward a successful treatment plan, a path that might have been far less clear without it. Her plea, echoed by others present, is for lawmakers to reject the proposed changes.
The implications extend far beyond cancer. Michael Davoli of the American Cancer Society Cancer Action Network emphasized the potential impact on patients battling diseases like ALS, where biomarker testing may hold the key to future cures. Jacqueline Nesbit, a Bronx resident and lung cancer survivor, added a poignant perspective: “I’ve watched for too long as people of color, low-income individuals, and neighbors of mine disproportionately shoulder the burden of disease like cancer. It’s largely because we’ve been shut out of advances like biomarker testing.”
The debate highlights a familiar tension: balancing the state budget with the critical needs of its citizens. But as Davoli forcefully stated, “We should not be balancing the state budget on the backs of cancer patients.” The governor's assurances of continued negotiation offer a glimmer of hope, but the fight to protect access to potentially life-saving technology is far from over. The stakes, quite simply, are too high to ignore.